atrial fibrilation
Merck drops oral anticoagulant
March 25, 2011Merck, Pradaxa, Xarelto, anticoagulant, atrial fibrilation, vorapaxar
Merck has given the rights to its oral anticoagulant betrixaban back to Portola Pharmaceuticals after a review of its late …
FDA issues Multaq liver warning
January 17, 2011Sales and Marketing FDA, Multaq, atrial fibrilation, dronedarone
US regulators have warned doctors and patients about the risk of severe liver injury associated with Sanofi-Aventis’ atrial fibrillation (AF) …
FDA approves Boehringer’s Pradaxa
October 20, 2010Sales and Marketing Boehringer, Pradaxa, atrial fibrilation
Boehringer Ingelheim’s Pradaxa has stolen a march over its rivals by being the first new oral anticoagulant to reach the …
FDA committee backs Pradaxa
September 23, 2010Sales and Marketing Boehringer, Pradaxa, atrial fibrilation
An FDA committee has voted unanimously in favour of approving Pradaxa for stroke prevention in patients with atrial fibrillation. The …
Sanofi’s Multaq in pole position for AF market
September 6, 2010Sales and Marketing Multaq, Sanofi-Aventis, atrial fibrilation
New European Society of Cardiology guidelines on treating atrial fibrillation (AF) include a recommendation for Sanofi-Aventis’ Multaq. The endorsement is …
Pradaxa, Xarelto and apixaban vie for attention
September 6, 2010Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation
New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …
Novel anticoagulants set to lead atrial fibrillation market
July 9, 2010Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation
Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …
New anti-clotting drugs: stopping the silent killers
June 28, 2010Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis
Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …
Early halt for successful apixaban trial
June 14, 2010Research and Development apixaban, atrial fibrilation
Pfizer and Bristol-Myers Squibb’s atrial fibrillation treatment apixaban has performed so well in a phase III trial that it has …
Merck’s Brinavess performs in phase III
May 18, 2010Research and Development Brinavess, Merck & Co, atrial fibrilation
Merck & Co’s heart disorder drug Brinavess has proved superior to rival amiodarone in reducing rates of atrial fibrillation in …
Latest content
Five Facts about cardiovascular disease
